The European Neurotech Investing and Partnering Summit 2011

Helsinki, Finland
Wednesday, September 07, 2011

 
 

Agenda
Grand Marina - Helsinki Finland

Wednesday September 7, 2011





7:30 

Breakfast & Registration




8:30

Welcome

  The Global Neurotechnology Industry 2011 
Casey Lynch, Managing Director, NeuroInsights

CNS Financing Trends and Models
Bruce Leuchter, Managing Director, Investment Banking, OPN Capital


9:00


Investing in Neurotech - Panel Discussion


A diverse panel of private, public and strategic investors will discuss their investment strategies. What are investors looking for to balance the risks and opportunities in neurotech? What are the benefits of business models in devices, pharmaceuticals, diagnostics and information technology in the EU? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?

Moderator: Killu Sanborn, Director of Business Development, Oxford Finance

Johan Christenson, Partner, HealthCap

Kent Hansen, Deutsche Bank Private Equity

Thom Rasche, Partner, Early Bird Venture Capital

Carole Nuechterlein, Head, Roche Venture Fund


10:00 


Networking and Refreshment Break


10:30


Alzheimer's and Cognitive Disorders


As the population ages, the market for Alzheimer's and cognitive disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon for symptom improvement and disease modification from drug and device companies?

Session Chair: Alexandra Goll, General Partner, TVM Capital

Konrad Glund, CEO, Probiodrug

Hampus Hillerstrom, Executive VP & CBO, NeuroPhage

Loic Maurel, CEO, ExonHit

   

11:30

Strategies for CNS Drug and Device Development


Intelligent preclinical screening and clinical trial design is critical to the success of any neurotech venture. The moderator will lead an insider panel in a discussion of specific tactics for improving drug and device development to navigate a path to approval. Case studies will demonstrate lessons learned in Alzheimer's, Parkinson's, depression, pain and more.

Session Chair: John Reppas, Director of Public Policy, Neurotech Industry Organization

Rick Stewart, Chairman and CEO, Ricanto

Beth Fordham-Meier, VP, Licensing and IP, Targacept

Vanessa Edwards, Partner, EU Regulatory Practice, K&L Gates

12:30    

Lunch

 
Lunch Keynote:
Best Practices for Pre-Clinical Disease Models for Efficacy Studies
Juha Yrjanheikki, Managing Director,
Cerebricon

 2:00

Movement Disorders: Parkinson's, Huntington's, and ALS

 

Exciting developments are in the pipeline for slowing progression of some of the most vexing neurological conditions like ALS, Huntinton's and Parkinson's.  What is the latest science behind new targets for these disorders. Can active doctor and patient populations and high prices offset small markets in orphan indications?

 


Session Chair:
Alethia de Leon, Head of Search and Evaluation, Neuroscience & Opthal., Global Business Development & Licensing, Novartis

Patrik Dahlen, CEO,
NeuroSearch

Juhani Ladenpera, CEO,
Hermo Pharma

Ulf Ljungberg, President and CEO, NeuroNova


Sjaak Deckers, CEO, Sapiens Steering
Brain Stimulation

 3:00

Internal and External Research & Development


What is in the pipeline at Big Pharma, Big Biotech and Big Medtech? Where are companies focusing internal versus external resources? How can outlicensing and spin out opportunities be leveraged? What opportunities exist for discovery partnerships and early development collaborations?

Session Chair: Hakan Goker, Principal, Aescap Venture

Jeffrey Erb, Business Development, Alliances, and IP Management, Medtronic

Mark Farmery, Neuroscience Business Development, AstraZeneca

Theo Meert, Head of Neuroscience,
Johnson & Johnson

Shafique Virani, Global Head, CNS Bus. Dev. and Licensing, Hoffmann La-Roche

 

 4:00

Networking and Refreshment Break


 4:30


Acute and Traumatic Injury: Stroke and TBI 


New hope is emerging for treatments of major traumatic injuries to the central nervous system. While highly challenging, companies are leveraging innovative financing to address these unmet markets.

Session Chair: Andreas Jeromin, Business Development, Banyan Biomarkers 


Mikael Bronnegard, CEO, NeuroVive Pharmaceuticals

Brian Leuthner, CEO,
Edge Therapeutics

Don Picker, CEO, Sinapis Pharma

Daniel Green, CEO,
Phagenesis Ltd.


  5:30


Networking Reception



 

Thursday September 8, 2011



7:30 


Breakfast & Registration

   
8:30  Creating a Rising Tide for the Brain Industry
   
  John Reppas, Director of Public Policy, Neurotechnology Industry Organization (NIO)

Daniel Ritter, Partner, K&L Gates, NIO Policy Counsel


8:50


Partnering, Licensing and Acquisitions in Neurotech


Big pharma, biotech and medtech are increasingly looking to smaller firms to provide innovative product candidates to fill pipelines. What are current trends in licensing and acquisitions? What are priority indications and stage of development requirements? What are the opportunities for neurodevice companies and who is interested in acquiring novel technology?

Session Chair: Francesco de Rubertis, Partner, Index Ventures

Richard Brudnick, Senior Director Business Development, Biogen Idec

Lubor Gaal, Head of Europe, Strategic Transactions Group, Bristol-Myers Squibb

Hans Christian Keller, Associate Director, Business Development, Lundbeck

Erik Lund, Director Worldwide Licensing, Merck


10:00 


Networking and Refreshment Break


10:30


Novel Drug, Device and Diagnostic Platforms

  Companies present novel approaches to tackling the brain and nervous system including brain mapping technology, neuromodulation platforms, diagnostic software, blood brain barrier penetration, and simulation technology for drug development.
 
Session Chair: Olivier Litzka, Partner, Edmond de Rothschild Investment Partners

Serge Bischoff, Co-Founder, President and CEO, Rhenovia Pharma

Willem van Weperen, CEO, toBBB

Janne Huhtala, CFO, Nexstim

Andrew Blackwell, CSO, Cambridge Cognition
 

11:30

Next Generation Psychiatry


Schizophrenia, anxiety, depression, ADHD, and other psychiatric illnesses represent a large portion of the neurotech market. What are the most promising next generation treatments? How will devices and diagnostics change the treatment landscape?

Session Chair: Bruce Leuchter, Managing Director, OPN Capital Markets

Erik Buntinx, CEO, PharmaNeuroBoost

Eric Meier, CEO, NeoStim

Timo Veromaa, CEO, Biotie Therapies

Dinah Weissmann, CEO, BioCortech

12:30

Lunch

 

 

2:00

Cutting Edge Translational Research and The Future of Treatment Development

 

This session will feature selected cutting-edge research projects and licensing opportunities from academia and research institutes. How do these novel projects shift the future of CNS  treatment development? Where should research be headed to avoid the problems of past generation therapeutics and devices?

Session Chair: Casey Lynch, Managing Director, NeuroInsights


“The role of environment, genes and brain development on CNS drug effects

Eero Castren, Research Director, Neuroscience Center,
University of Helsinki

"New animal models of neurodegeneration, depression and anxiety"
Wolfgang Wurst, Director of the Institute of Developmental Genetics at the National Research Centre for Environment and Health  and Professor at University Munich

"IMANE: Collaborating to develop next generation intelligent neurodevices"
Peter Bergsma, VP Business Development, Neurotech SA

3:00 


Refreshment Break, One-on-One Meetings


5:00

Conference Concludes

 

Contact Information


     

    

                

Copyright © 2014 The Active Network, Inc.